UY25774A1 - Tabletas de valaciclovir que contienen dioxido de silicio coloidal - Google Patents
Tabletas de valaciclovir que contienen dioxido de silicio coloidalInfo
- Publication number
- UY25774A1 UY25774A1 UY25774A UY25774A UY25774A1 UY 25774 A1 UY25774 A1 UY 25774A1 UY 25774 A UY25774 A UY 25774A UY 25774 A UY25774 A UY 25774A UY 25774 A1 UY25774 A1 UY 25774A1
- Authority
- UY
- Uruguay
- Prior art keywords
- valacyclovir
- tablet
- filler
- silicon dioxide
- lubricant
- Prior art date
Links
- 229940093257 valacyclovir Drugs 0.000 title abstract 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title abstract 4
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 title abstract 4
- 239000000377 silicon dioxide Substances 0.000 title abstract 2
- 235000012239 silicon dioxide Nutrition 0.000 title abstract 2
- 239000000945 filler Substances 0.000 abstract 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 2
- 239000000314 lubricant Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 229910002092 carbon dioxide Inorganic materials 0.000 abstract 1
- 239000001569 carbon dioxide Substances 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 235000010980 cellulose Nutrition 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000001050 lubricating effect Effects 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229910052710 silicon Inorganic materials 0.000 abstract 1
- 239000010703 silicon Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9501127.6A GB9501127D0 (en) | 1995-01-20 | 1995-01-20 | Tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25774A1 true UY25774A1 (es) | 2000-10-31 |
Family
ID=10768317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25774A UY25774A1 (es) | 1995-01-20 | 1999-10-28 | Tabletas de valaciclovir que contienen dioxido de silicio coloidal |
| UY25778A UY25778A1 (es) | 1995-01-20 | 1999-10-29 | Proceso para preparar tabletas de valaciclovir que contiene dioxido de silicio coloidal |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25778A UY25778A1 (es) | 1995-01-20 | 1999-10-29 | Proceso para preparar tabletas de valaciclovir que contiene dioxido de silicio coloidal |
Country Status (38)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
| CA2243237C (en) * | 1996-01-19 | 2008-09-02 | Glaxo Group Limited | Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application |
| AR017512A1 (es) * | 1997-08-22 | 2001-09-12 | Smithkline Beecham Corp | Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas |
| AR016827A1 (es) * | 1997-08-22 | 2001-08-01 | Smithkline Beecham Corp | PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA |
| SI20624A (sl) * | 1998-12-18 | 2002-02-28 | Abbott Laboratories | Formulacija divalproeks natrija za kontrolirano sproščanje |
| GB0010446D0 (en) * | 2000-04-28 | 2000-06-14 | Glaxo Wellcome Kk | Pharmaceutical formulation |
| AP2003002900A0 (en) * | 2001-05-01 | 2003-12-31 | Pfizer Prod Inc | Method for manufacturing a low dose pharmaceutical composition |
| US7815936B2 (en) * | 2001-10-30 | 2010-10-19 | Evonik Degussa Gmbh | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
| WO2003040145A1 (en) * | 2001-11-05 | 2003-05-15 | Glaxo Group Limited | Anhydrous crystal form of valaciclovir hydrochloride |
| IL161969A0 (en) * | 2001-11-14 | 2005-11-20 | Teva Pharma | Synthesis and purification of valacyclovir |
| GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| EP1517678A2 (en) * | 2002-06-24 | 2005-03-30 | Ranbaxy Laboratories Limited | Process for the preparation of robust formulations of valacyclovir hydrochloride tablets |
| US20050051922A1 (en) * | 2002-09-20 | 2005-03-10 | Avinash Nangia | Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same |
| EP1551838B1 (en) * | 2002-10-16 | 2006-08-09 | Teva Pharmaceutical Industries Ltd. | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US20050059684A1 (en) * | 2002-10-16 | 2005-03-17 | Ben-Zion Dolitzky | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US20040109889A1 (en) * | 2002-12-04 | 2004-06-10 | Bunick Frank J. | Surface treatment composition for soft substrates |
| WO2004106338A1 (en) * | 2003-05-30 | 2004-12-09 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. | Novel crystalline forms of valacyclovir hydrochloride |
| TW200510414A (en) * | 2003-06-02 | 2005-03-16 | Teva Pharma | Novel crystalline forms of valacyclovir hydrochloride |
| US7632521B2 (en) * | 2003-07-15 | 2009-12-15 | Eurand, Inc. | Controlled release potassium chloride tablets |
| AR045637A1 (es) | 2003-09-12 | 2005-11-02 | Amgen Inc | Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio |
| DE10351448A1 (de) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| ATE301455T1 (de) * | 2003-12-09 | 2005-08-15 | Helm Ag | Pharmazeutische zubereitung enthaltend valaciclovir |
| US7344907B2 (en) * | 2004-11-19 | 2008-03-18 | International Business Machines Corporation | Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale |
| KR101116747B1 (ko) | 2004-12-06 | 2012-02-22 | 에스케이케미칼주식회사 | 안정성이 개선된 말레인산 암로디핀 약제 조성물 |
| DE602006017188D1 (de) | 2005-03-07 | 2010-11-11 | Bayer Schering Pharma Ag | Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs |
| EP1891071B1 (en) * | 2005-05-25 | 2012-02-22 | Eli Lilly And Company | Cyclopropanecarboxylate esters of acyclovir |
| EP1746098A1 (en) * | 2005-07-21 | 2007-01-24 | SOLMAG S.p.A. | Valacyclovir polymorphs and a process for the preparation thereof |
| WO2007090595A1 (en) * | 2006-02-06 | 2007-08-16 | Fidia Pharmaceutici S.P.A. | Solid formulations of valacyclovir hydrochloride |
| EP2023899A1 (en) * | 2006-05-10 | 2009-02-18 | Evonik Degussa GmbH | Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions |
| MX2008015253A (es) * | 2006-05-31 | 2008-12-17 | Vertex Pharma | Formulaciones de liberacion controlada. |
| EP2040684B1 (en) * | 2006-07-11 | 2013-01-23 | LEK Pharmaceuticals d.d. | Multiple unit tablets |
| US20080167325A1 (en) * | 2006-12-27 | 2008-07-10 | Bs Praveen Kumar | Valacyclovir compositions |
| US20090076039A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched valacyclovir |
| ITRM20080027A1 (it) * | 2008-01-18 | 2009-07-19 | Maria Balestrieri | Uso di aciclovir per il trattamento delle condilomatosi. |
| US20100124560A1 (en) * | 2008-11-14 | 2010-05-20 | Mcneil Ab | Multi portion intra-oral dosage form and use thereof |
| PL2407166T3 (pl) * | 2009-03-13 | 2014-01-31 | Toyama Chemical Co Ltd | Tabletka i granulowany proszek zawierające 6-fluoro-3-hydroksy-2-pirazynokarboksamid |
| CH703348A1 (de) * | 2010-06-29 | 2011-12-30 | Mepha Gmbh | Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen. |
| GB2515486A (en) * | 2013-06-24 | 2014-12-31 | Kraft Foods R & D Inc | Soluble Beverage Ingredients |
| KR101497508B1 (ko) * | 2013-12-20 | 2015-03-03 | 한국유나이티드제약 주식회사 | 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법 |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| WO2020049536A1 (en) * | 2018-09-07 | 2020-03-12 | Jubilant Generics Limited | Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof |
| CN110279667B (zh) * | 2019-07-30 | 2023-02-10 | 珠海润都制药股份有限公司 | 一种盐酸伐昔洛韦片及其制备方法 |
| US20230201234A1 (en) * | 2020-06-01 | 2023-06-29 | Shilpa Medicare Ltd | Fast dispersible pharmaceutical composition comprising capecitabine |
| PE20230850A1 (es) * | 2020-12-01 | 2023-05-23 | Lg Chemical Ltd | Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion |
| CN119789849A (zh) * | 2022-08-31 | 2025-04-08 | 阿斯利康(瑞典)有限公司 | 药物制剂 |
| WO2026139414A1 (en) | 2024-12-24 | 2026-07-02 | Dermax Sa | Valacyclovir oral suspensions, their preparation, storage and use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1259924A (en) * | 1985-03-25 | 1989-09-26 | Wallace E. Becker | Pharmaceutical tableting method |
| AP160A (en) * | 1987-08-15 | 1991-11-18 | The Wellcome Foundation Ltd | Therapeutic acyclic nucleosides. |
| ATE82680T1 (de) * | 1988-05-04 | 1992-12-15 | Smith Kline French Lab | Kautablette. |
| UA37214C2 (uk) * | 1991-01-30 | 2001-05-15 | Дзе Веллкам Фаундейшн Лімітед | Таблетки, що диспергуються у воді, та спосіб їх виготовлення |
| GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| GB9317146D0 (en) * | 1993-08-18 | 1993-10-06 | Wellcome Found | Therapeutic combinations |
| GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
-
1995
- 1995-01-20 GB GBGB9501127.6A patent/GB9501127D0/en active Pending
-
1996
- 1996-01-19 NZ NZ298846A patent/NZ298846A/en not_active IP Right Cessation
- 1996-01-19 KR KR1019970704915A patent/KR100412298B1/ko not_active Expired - Lifetime
- 1996-01-19 AP APAP/P/1997/001057A patent/AP666A/en active
- 1996-01-19 CA CA002210891A patent/CA2210891C/en not_active Expired - Fee Related
- 1996-01-19 EA EA199700123A patent/EA000276B1/ru not_active IP Right Cessation
- 1996-01-19 AT AT96900626T patent/ATE190483T1/de not_active IP Right Cessation
- 1996-01-19 IN IN100MA1996 patent/IN181318B/en unknown
- 1996-01-19 CN CNB2003101029136A patent/CN1313081C/zh not_active Expired - Fee Related
- 1996-01-19 EP EP96900626A patent/EP0806943B1/en not_active Expired - Lifetime
- 1996-01-19 WO PCT/GB1996/000111 patent/WO1996022082A1/en not_active Ceased
- 1996-01-19 HU HU9801872A patent/HU226131B1/hu not_active IP Right Cessation
- 1996-01-19 CN CN96192661A patent/CN1131026C/zh not_active Expired - Fee Related
- 1996-01-19 GE GEAP19963844A patent/GEP20022752B/en unknown
- 1996-01-19 MY MYPI96000222A patent/MY126346A/en unknown
- 1996-01-19 EE EE9700352A patent/EE03336B1/xx not_active IP Right Cessation
- 1996-01-19 IL IL11683096A patent/IL116830A/xx not_active IP Right Cessation
- 1996-01-19 ZA ZA96448A patent/ZA96448B/xx unknown
- 1996-01-19 DK DK96900626T patent/DK0806943T3/da active
- 1996-01-19 DE DE69607146T patent/DE69607146T2/de not_active Expired - Lifetime
- 1996-01-19 TR TR97/00657T patent/TR199700657T1/xx unknown
- 1996-01-19 UA UA97084269A patent/UA68325C2/uk unknown
- 1996-01-19 PT PT96900626T patent/PT806943E/pt unknown
- 1996-01-19 CZ CZ0229297A patent/CZ296514B6/cs not_active IP Right Cessation
- 1996-01-19 US US08/875,172 patent/US5879706A/en not_active Expired - Lifetime
- 1996-01-19 SK SK964-97A patent/SK282030B6/sk not_active IP Right Cessation
- 1996-01-19 RO RO97-01333A patent/RO118175B1/ro unknown
- 1996-01-19 ES ES96900626T patent/ES2145425T3/es not_active Expired - Lifetime
- 1996-01-19 BR BR9606769A patent/BR9606769A/pt not_active IP Right Cessation
- 1996-01-19 AU AU44534/96A patent/AU710823B2/en not_active Ceased
- 1996-01-19 JP JP52212696A patent/JP3350055B2/ja not_active Expired - Fee Related
-
1997
- 1997-07-16 OA OA70052A patent/OA10500A/en unknown
- 1997-07-18 FI FI973062A patent/FI119722B/fi not_active IP Right Cessation
- 1997-07-18 NO NO19973327A patent/NO311488B1/no not_active IP Right Cessation
- 1997-07-18 PL PL96321361A patent/PL185307B1/pl not_active IP Right Cessation
- 1997-08-14 BG BG101831A patent/BG63187B1/bg unknown
-
1999
- 1999-10-28 UY UY25774A patent/UY25774A1/es unknown
- 1999-10-29 UY UY25778A patent/UY25778A1/es not_active IP Right Cessation
-
2000
- 2000-06-14 GR GR20000401364T patent/GR3033677T3/el not_active IP Right Cessation
- 2000-08-23 CY CY0000042A patent/CY2182B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25778A1 (es) | Proceso para preparar tabletas de valaciclovir que contiene dioxido de silicio coloidal | |
| AR002270A1 (es) | Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina | |
| PT1119543E (pt) | N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y | |
| HUT62467A (en) | Process for producing locally applicable pharmaceutical compositions comprising allylamine derivative, against fungus infection of nails | |
| CZ226195A3 (en) | The use of lamotrigin for preparing medicaments intended for treating neuronal degeneration caused by aids | |
| EE04700B1 (et) | Segamisest sõltumatud toimeainet aeglustatult vabastavad mitmeosalised ravimvormid ja nende valmistamismeetodid | |
| MX9204394A (es) | Derivados de amida del antibiotico a 40926, procedimiento para su preparacion y composicion farmaceutica que los contienen. | |
| ES2173883T3 (es) | Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion. | |
| WO2001051473A8 (de) | 1,2-diarylbenzimidazole zur behandlung von krankungen die mit einer microglia-aktivierung assoziiert sind | |
| HUT52379A (en) | Process for producing ribonucleotide reductase inhibitor, antiviral combinations comprising same, as well as pharmaceutical compositions comprising these combinations as active ingredient | |
| BG100599A (en) | Antiviral form and therapeutical method | |
| FR2701260B1 (fr) | Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments. | |
| ES2101747T3 (es) | Penciclovir y famciclovir y derivados de guanina relacionados para el tratamiento de infecciones por vih-1. | |
| ES2072386T3 (es) | Derivados del penciclovir para el tratamiento de las infecciones de hepatitis-b. | |
| MC1930A1 (fr) | Produit antiviral | |
| ES2191908T3 (es) | 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido. | |
| ATE141506T1 (de) | Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff | |
| CA2120001A1 (en) | Flavopereirine-based pharmaceutical composition and use thereof for treating hiv | |
| AR005551A1 (es) | Un producto de combinación farmacéutico que comprende un nucleósido análogo e inmunosupresores en combinación con un agente citotóxico para el tratamiento de infecciones con el virus del herpes simple | |
| BR0109770A (pt) | Uso de galantamina para o tratamento do comportamento neuropsiquiátrico associado com a doença de alzheimer | |
| TR200102009T2 (tr) | Serebral işlemi profilaksı ve tedavisi için formül I'e göre bileşiklerin kullanımı | |
| ES2049711T1 (es) | Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de la cistinuria. | |
| MX9302818A (es) | Agente para incrementar somatostatina o para inhibir la reduccion de somatostatina. | |
| AR005456A1 (es) | Comprimidos y tabletas farmaceuticas que contienen 2-(2-(2-amino-9h-purin-9-il)etil)-1,3-propanodiol diacetato (famcicloviri) yprocedimiento para obtenerlos | |
| YU20902A (sh) | Primena karbinola supstituisanih sa 2-imidazolilom za izradu medikamenta za lečenje ili profilaksu oboljenja izazvanih ishemičkim stanjima |